Pri-Med Dallas | July 2025

Thursday−Friday, July 10–11|Dallas, TX

Pri-Med Dallas | Regional CME/CE Conference

Friday, July 11 2025

12:40–1:40pm

Industry Theater

Empowering Treatment Choice with Spravato

Industry Theater 1, Ballroom A4, Level 2

Description

“Empowering Treatment Choice With SPRAVATO®” is an educational program focusing on care options for adult patients with treatment-resistant depression (TRD).

Empowering Treatment Choice With SPRAVATO® (cp-428154v6)

-Review the patient experience and unmet need in treatment-resistant depression (TRD)—major depressive disorder (MDD) with inadequate response to at least 2 oral -antidepressants of adequate dose and duration
-Understanding the mechanism of action for SPRAVATO® (esketamine) CIII nasal spray
-Clinical efficacy data in TRD for SPRAVATO® alone or in combination with an oral antidepressant
-5-year results from a long-term, open-label safety study of SPRAVATO®
-Two ways to connect patients to care with SPRAVATO®: treat or refer
-Important Safety Information

Faculty

Sponsored by

  • Johnson & Johnson